and was launched on the Indian market in the last quarter of 2014. In Japan, a key milestone was achieved in 2014 with the licensure of Squarekids, a quadrivalent pediatric combination vaccine offering protection against diphtheria, tetanus, pertussis and polio. Squarekids was co-developed with the company's partner, Kitasato Daiichi Sankyo Vaccine. The commercial launch took place in December 2015. Sanofi Pasteur is the primary developer and manufacturer of polio vaccines, with both Oral Polio Vaccines (OPV) and Injectable Polio Vaccines (IPVs) in its portfolio worldwide. In 2015, Sanofi Pasteur delivered 27 million doses of IPV standalone to UNICEF for GAVI countries. In India, ShanIPV manufactured by Shantha, and reserved for the Indian market, received marketing authorization in 2015 and was launched in December 2015. Influenza Vaccines Sanofi Pasteur engages in the production and marketing of influenza vaccines with approximately 220 million doses delivered in 2015. Sanofi Pasteur expects the global demand for influenza vaccines to continue to grow within the next decade due to increased disease awareness, growth in emerging markets and expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza. Sanofi Pasteur has two influenza vaccines that are sold worldwide, Fluzone and Vaxigrip. Sanofi Pasteur remains focused on meeting the increasing demand for seasonal influenza vaccines through the launch of innovative vaccines. The differentiated product strategy is strengthening the leadership of Sanofi Pasteur in the influenza market with the following products: Fluzone High-Dose vaccine, launched in the U.S. in 2010, was specifically designed to generate a more robust immune response against influenza in people aged 65 and older and provide greater protection against influenza. In November 2014, the FDA changed the prescribing information for Fluzone High-Dose vaccine to document the superior clinical benefit for Fluzone High-Dose vaccine, compared to the standard dose of Fluzone vaccine (Fluzone High-Dose vaccine was 24% more effective than Fluzone vaccine in a large-scale efficacy study). In 2015, Fluzone High-Dose continued to generate strong sales growth; Fluzone Quadrivalent vaccine is a quadrivalent inactivated influenza vaccine containing two type A antigens and two type B antigens. Compared to the trivalent influenza vaccine, the addition of a second B strain to the vaccine provides increased protection against the most prevalent circulating strains. In 2013, Sanofi Pasteur obtained FDA authorization for Fluzone Quadrivalent to be commercialized in the U.S. for children over six months, adolescents and adults. Since 2014, Fluzone Quadrivalent/FluQuadri vaccine has launched in approximately 20 other countries, including Mexico and Canada; Intradermal (ID) trivalent influenza vaccines (Intanza/IDflu launched in 2010 in Australia, Canada, the E.U. and various other countries and Fluzone ID launched in the U.S. in 2011) also contribute to Sanofi Pasteur’s flu differentiation strategy. The ID vaccines represent new offer efficiency and provide simplicity of administration. In 2015, Fluzone ID Quadrivalent was launched in the U.S.; Vaxigrip vaccine is a trivalent vaccine that is licensed in approximately 150 countries worldwide for people approximately 6 months old. Sanofi Pasteur is planning to launch a quadrivalent formulation of Vaxigrip in the coming years. The E.U. license for Vaxigrip quadrivalent influenza vaccine (QIV) + 3 years is expected in the second half of 2016 with a launch starting in 2017. With regards to Vaxigrip QIV 6-35 months, a license application in the E.U. is expected to be submitted in the course of 2018. Adult and Adolescent Boosters Adacel, the first trivalent adolescent and adult booster offering protection against diphtheria, tetanus and pertussis, was licensed and launched in the U.S. in 2005. Since its launch in the U.S. and expansion to approximately 60 countries, approximately 140 million doses of Adacel have been sold. This vaccine plays an important role in efforts to control pertussis, by preventing the dis
sanofi-titr part10%87 (RHPP:EN Paris)
54, Rue La Boétie
Phone: 33 1 53 77 40 00
Fax: 33 1 53 77 42 96www.sanofi.com
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for RHPP.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact SANOFI-TITR PART10%87, please visit www.sanofi.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.